Bimagrumab + Semaglutide: Metabolic Gamechanger?
Combining bimagrumab with semaglutide yields striking improvements in both body composition and metabolic health among obese patients, reported in a *Nature Medicine* phase II study [https://conscienhealth.org/2026/03/09/striking-results-with-bimagrumab-and-semaglutide/]. This combo therapy offers a promising route for those with type 2 diabetes and obesity. What's the timeline for FDA approval?
The BELIEVE trial, presented at the American Diabetes Association Scientific Sessions, involved 507 patients with obesity. Participants had a BMI of 30 or higher, or 27 or higher with at least one comorbidity like hypertension or sleep apnea, and had previously failed behavioral weight loss attempts. The trial randomized individuals across 26 centers in the US, Australia, and New Zealand. Semaglutide, a GLP-1 receptor agonist, mimics the glucagon-like peptide-1 hormone to regulate digestion and blood sugar. It stimulates insulin secretion when glucose levels are high and reduces glucagon secretion during hyperglycemia. Common side effects include nausea and diarrhea. Bimagrumab, initially developed for sarcopenia, binds to activin receptors to stimulate muscle growth. It inhibits the activin receptor type-2B (ActRIIB), blocking myostatin-induced SMAD pathway signaling to improve skeletal muscle formation. Bimagrumab is administered intravenously once a month due to its long half-life. In the BELIEVE trial, the highest dose combination of bimagrumab and semaglutide led to an average weight loss of 17.8 kg at 48 weeks, compared to 9.3 kg with bimagrumab alone and 14.2 kg with semaglutide alone. Weight loss continued through 72 weeks. Participants receiving bimagrumab only experienced a 10.8% weight loss, entirely from fat mass, with a 2.5% increase in lean mass. Semaglutide monotherapy resulted in a 15.7% body weight loss, with 71.8% of the loss from fat mass. The bimagrumab/semaglutide combination led to a 22.1% weight loss, with 92.8% of the weight loss from fat mass, preserving lean mass. The obesity treatment pipeline is robust, with over 80 companies developing more than 100 therapies. Eli Lilly's orforglipron, an oral GLP-1 therapy, is anticipated to receive FDA approval in 2026. Novo Nordisk's oral semaglutide was approved by the FDA in late December 2025, with a full commercial rollout expected in early 2026.
